FTY720, an immunosuppressant, attenuates chronic pancreatitis in rats by suppressing T-cell infiltration

Pancreas

Volumn 30, Issue 3, 2005, Pages

  Okamoto, Tetsu ^a   Yamada, Tamaki ^b   Kuno, Atsushi ^a   Ogawa, Kumiko ^a   Tang, Mingxi ^a   Sano, Hitoshi ^a   Nakao, Haruhisa ^a   Kataoka, Hiromi ^a   Shirai, Tomoyuki ^a   Itoh, Makoto ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Okazaki City Medical Association   (Japan)

Author keywords

Chronic pancreatitis; Fibrosis; FTY720; Immunosuppressant; T cell

Indexed keywords

DRUG DERIVATIVE; FINGOLIMOD; GAMMA INTERFERON; HYDROXYPROLINE; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; PEROXIDASE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; BODY WEIGHT; CHRONIC PANCREATITIS; DRUG EFFECT; GENETICS; IMMUNOLOGY; MALE; METABOLISM; ORGAN SIZE; PANCREAS; PATHOLOGY; PHYSIOLOGY; RAT; T LYMPHOCYTE; WISTAR RAT;

ANIMALS; BODY WEIGHT; HYDROXYPROLINE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MALE; ORGAN SIZE; PANCREAS; PANCREATITIS, CHRONIC; PEROXIDASE; PROPYLENE GLYCOLS; RATS; RATS, WISTAR; RNA, MESSENGER; SPHINGOSINE; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33644875851     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/01.mpa.0000157386.15898.3a     Document Type: Article

References (45)

1. Adachi K, Kohara T, Nakao N. Design, synthesis, and structure-activity relationship of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett. 1995;5:853-856.
2. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160:5037-5044.
3. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000;164:5761-5770.
4. Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin graft survival and synergistic effects in combination with cyclosporine in rats. Transplant Proc. 1996;28:1056-1059.
5. Hoshino Y, Suzuki C, Ohtsuki M, et al. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc. 1996;282:1060-1061.
6. Matsuura M, Imayoshi T, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-and collagen-induced arthritis in rats. Int J Immunol. 2000;22:323-331.
7. Kitabayashi H, Isobe M, Watanabe N, et al. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol. 2000;35:410-416.
8. Okazaki H, Hirata D, Kamimura T, et al. Effects of FTY720 in MPL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002;29:707-716.
9. Yang Z, Chen M, Fialkow LB, et al. The immune modulator FTY720 prevents autoimmune diabetes in nonobese diabetic mice. Clin Immunol. 2003;107:30-35.
10. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003;305:70-77.
11. Matsuura M, Imayoshi T, Chiba K, et al. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res. 2000;49:404-410.
12. Sparmann G, Behrend S, Merkord J, et al. Cytokine mRNA levels and lymphocyte infiltration in pancreatic tissue during experimental chronic pancreatitis induced by dibutylin dichloride. Dig Dis Sci. 2001;46:1647-1656.
13. Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology. 2000;118:573-581.
14. Mori Y, Yokoyama J, Nishimura M, et al. A new diabetic strain of rat with exocrine pancreatic insufficiency. In: Tiengo A, Del Prato S, Alberti KG, et al, eds. Diabetes Secondary to Pancreatopathy. Amsterdam: Elsevier; 1988:107-112.
15. Ohashi K, Kim J-H, Hara H, et al. WBN/Kob rats: a new spontaneously occurring model of chronic pancreatitis. Int J Pancreatol. 1989;6:231-247.
16. Hashimoto T, Yamada T, Yokoi T, et al. Apoptosis of acinar cells is involved in chronic pancreatitis in WBN/Kob rats: role of glucocorticoids. Pancreas. 2000;21:296-304.
17. Yamada T, Hashimoto T, Sogawa M, et al. Involvement of T cells in development of chronic pancreatitis in male Wistar Bonn/Kobori rats: protective effects of tacrolimus. Am J Physiol. 2001;281:G1397-G1404.
18. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated for a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1256-1265.
19. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int. 1994;7:S52-S57.
20. Finn WF. FK506 nephrotoxicity. Ren Fail. 1999;21:319-329.
21. Nieto Y, Russ P, Everson G, et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2000;261:109-111.
22. Sastry J, Young S, Shaw PJ. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33:867-868.
23. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf. 1996;14:406-423.
24. Gomez JA, Molero X, Vaquero E, et al. Vitamin E attenuates biochemical and morphological features with development of chronic pancreatitis. Am J Physiol. 2004;287:162-169.
25. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;61:200-205.
26. Kuno A, Yamada T, Masuda K, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003;124:1010-1019.
27. Yamada T, Kuno A, Masuda K, et al. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats. J Pharmacol Exp Ther. 2003;307:17-23.
28. Watanabe T, Katsura Y, Yoshitake A, et al. IPAP: Image processor for analytical pathology. J Toxicol Pathol. 1994;7:353-361.
29. Grisham MB, Benoit JN, Granger DN. Assessment of leukocyte involvement during ischemia and perfusion of intestine. Methods Enzymol. 1990;186:729-741.
30. Blumenkrantz N, Asobe-Hansen G. A quick and specific assay for hydroxyproline. Anal Biochem. 1973;55:288-291.
31. Yan H, Suzuki K, Li XK, et al. Immunosuppressive effect of FTY 720 on autoimmune diabetes models. Transplant Proc. 1998;30:3436-3437.
32. Kitabayashi H, Isobe M, Watanabe N, et al. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol. 2000;35:410-416.
33. Shindo M, Mullin GE, Braun-Elwert L, et al. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB). Clin Exp Immunol. 1996;105:254-259.
34. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, et al. IFN-γ gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol. 1995;154:4874-4882.
35. Thomas HE, Parker JL, Schreiber RD, et al. IFN-γ action on pancreatic β cells causes class I MHC upregulation but not diabetes. J Clin Invest. 1998;15:1249-1257.
36. Hill NJ, Van Gunst K, Sarvetnick N. Th1 and Th2 pancreatic inflammation differentially affects homing of islet-reactive CD4 cells in nonobese diabetic mice. J Immunol. 2003;170:1649-1658.
37. Xie MJ, Motoo Y, Su SB, et al. Expression of tumor necrosis factor-α, interleukin-6, and interferon-γ in spontaneous chronic pancreatitis in the WBN/Kob rat. Pancreas. 2001;22:400-408.
38. Van Laethem JL, Deviere J, Resibois A, et al. Localization of transforming growth factor-β1 expression and its binding protein in human chronic pancreatitis. Gastroenterology. 1995;108:1873-1881.
39. Van Laethem JL, Robberecht P, Resibois A, et al. Transforming growth factor-β promotes development of fibrosis after repeated courses of acute pancreatitis in mice. Gastroenterology. 1996;110:576-582.
40. Lee M-S, Gu D, Feng D, et al. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-β1. Am J Pathol. 1995;147:42-52.
41. Schneider E, Schmid-Kotsas A, Zhao J, et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol. 2001;281:C532-C543.
42. Apte MV, Haber PS, Darby SJ, et al. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999;44:534-541.
43. Haber PS, Keogh QW, Apte MV, et al. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am J Pathol. 1999;155:1087-1095.
44. Menke A, Yamaguchi H, Gress TM, et al. Extracellular matrix protein is reduced by inhibition of TGF-β1 in pancreatitis in the rat. Gastroenterology. 1997;113:295-303.
45. Su SB, Motoo Y, Xie MJ, et al. Expression of transforming growth factor-β in spontaneous chronic pancreatitis in the WBN/Kob rat. Dig Dis Sci. 2000;45:151-159.